Retina
Definition
Referral Criteria
Signs and Symptoms
Opthea discontinues development of sozinibercept in wet AMD
Opthea has discontinued development of sozinibercept in wet age-related macular degeneration, according to a press release.
<em>Demodex</em> Blepharitis Unveiled: Precision Diagnosis and Effective Treatments
This activity is supported by an educational grant from Tarsus Pharmaceuticals, Inc.
UBX1325 fails to meet primary analysis endpoint despite vision gains in DME
Intravitreal UBX1325 helped patients with diabetic macular edema gain vision but failed to meet its primary analysis endpoint in the ASPIRE clinical trial, according to a press release from Unity Biotechnology.
Phase 3 COAST trial of wet AMD combination therapy misses primary endpoint
The phase 3 COAST trial investigating 2 mg sozinibercept for the treatment of wet age-related macular degeneration in combination with 2 mg aflibercept did not meet its primary endpoint, according to a press release from Opthea.
nAMD, DME, and DR: Current Approaches in Reducing Treatment Burden
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Tyrosine Kinase Inhibitors: Transforming nAMD Treatment
This activity is supported by an educational grant from EyePoint Pharmaceuticals, Inc.
Tyrosine Kinase Inhibitors and Their Role in Redefining Retinal Care
This activity is supported by an educational grant from Ocular Therapeutix, Inc.